

Summary Public Assessment Report

Kalciumklorid Abboxia (calcium chloride dihydrate)

SE/H/2596/001/MR

Summary Public Assessment Report

Kalciumklorid Abboxia
calcium chloride dihydrate

Solution for injection, 0,46 mmol/ml

This is a summary of the public assessment report (PAR) for Kalciumklorid Abboxia. It explains how the assessment was made and why the authorisation was recommended as well as the conditions of use. It is not intended to provide practical advice on how to use the product.

For practical information about the use of the product, patients should read the package leaflet or contact their doctor or pharmacist.

What is Kalciumklorid Abboxia and what is it used for?

The product is a medicine with 'well-established use'. This means that the medicinal use of the active substance of the product is well established in the European Union for at least ten years, with recognised efficacy and an acceptable level of safety.

The product is used for the treatment of adults and children who have low levels of calcium, too high levels of magnesium or potassium in the blood as well as having too high dose of calcium channel blocker (medicine to treat high blood pressure).

How does Kalciumklorid Abboxia work?

Calcium is, among other things, essential for the function of the nervous system, muscles, heart, cell membranes and skeleton. Calcium is essential for several physiological processes.

How is Kalciumklorid Abboxia used?

The pharmaceutical form is solution for injection for intravenous use.

Please read section 3 of the package leaflet for detailed information on dosing recommendations, the route of administration, and the duration of treatment.

The medicine can only be obtained with a prescription in Sweden.

What benefits of Kalciumklorid Abboxia have been shown in studies?

As calcium chloride dihydrate is a well-known substance, and its use in the treatment of *hypocalcaemia, calcium channel blocker overdose, hypermagnesemia or hyperkalaemia in adults and children* is well established, the applicant presented data from the scientific literature. The literature provided confirmed the efficacy and safety of calcium chloride dihydrate in the treatment of the above-mentioned indication.

What are the possible side effects from Kalciumklorid Abboxia?

For the full list of side effects, see section 4 of the package leaflet.

For the full list of restrictions, see the package leaflet.

Why is Kalciumklorid Abboxia approved?

The Swedish Medical Products Agency decided that the benefits are greater than its risks and recommended that it can be approved for use.

What measures are being taken to ensure the safe and effective use of Kalciumklorid Abboxia?

A risk management plan has been developed to ensure that the product is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet, including the appropriate precautions to be followed by healthcare professionals and patients.

Known side effects are continuously monitored. Furthermore, new safety signals reported by patients/healthcare professionals will be monitored/reviewed continuously as well.

Other information about Kalciumklorid Abboxia

The full PAR for Kalciumklorid Abboxia can be found on the following website: [MRI - Home](#). For more information about treatment with Kalciumklorid Abboxia, please read the package leaflet or contact your doctor or pharmacist.

This summary was last updated in 2025-05.